Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release

Kamaly, Nazila; Yameen, Basit; Wu, Jun; Farokhzad, Omid C.

doi:10.1021/acs.chemrev.5b00346

Cited by 2,207 publications

(1,578 citation statements)

References 594 publications

Supporting

Mentioning

1,453

Contrasting

Unclassified

Order By: Relevance

“…20,21 Therefore, there is an incentive to fabricate a targeting delivery system such that a high local concentration of Tβ4 can be built up within the infarct and side effects to other organs would be reduced. 22,23 There is abundant extracellular matrix (ECM) in various tissue microenvironments. After injury, a dramatic change in the composition of the ECM occurs, providing mechanical support to the injured tissue and directly modulating the inflammatory and reparative responses.…”

mentioning

confidence: 99%

Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles

Huang

Song

Pang

et al. 2017

IJN

View full text Add to dashboard Cite

Purpose Thymosin beta 4 (Tβ4) has multiple beneficial facets for myocardial injury, but its efficiency is limited by the low local concentration within the infarct. Here, we established a Tβ4 delivery system for cardiac repair based on the interaction between the abundant fibrin in the infarct zone and the fibrin-targeting moiety clot-binding peptide cysteine–arginine–glutamic acid–lysine–alanine (CREKA). Methods and results CREKA and Tβ4 were conjugated to nanoparticles (CNP–Tβ4). In vitro binding test revealed that CNP–Tβ4 had a significant binding ability to the surface of fibrin clots when compared to the control clots (NP–Tβ4). Based on the validation of fibrin expression in the early stage of ischemia injury, CNP–Tβ4 was intravenously administered to mice with acute myocardial ischemia–reperfusion injury. CNP–Tβ4 revealed a stronger fibrin-targeting ability than the NP–Tβ4 group and accumulated mainly in the infarcted area and colocalized with fibrin. Subsequently, treatment with CNP–Tβ4 resulted in a better therapeutic effect. Conclusion CRKEA modification favored Tβ4 accumulation and retention in the infarcted region, leading to augmented functional benefits. Fibrin-targeting delivery system represents a generalizable platform technology for regenerative medicine.

show abstract

mentioning

confidence: 99%

Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles

Huang

Song

Pang

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…As the most attractive and efficient polymeric nanocarrier, PLGA nanoparticles are widely used in clinical applications. [28][29][30][31][32] Additionally, polyethylene glycolated (PEGylated) PLGA nanoparticles have been developed to improve bioavailability and antitumor targeting further. 28,33,34 In other words, besides the hydrophobic region of PLGA being efficient in hydrophobic drug encapsulation, the hydration on the hydrophilic PEG corona can further prevent nanocarriers from aspecific protein adsorption and reticuloendothelial system clearance for prolonging blood circulation in vivo.…”

Section: Chen Et Almentioning

confidence: 99%

Dual tumor-targeted poly(lactic-<em>co</em>-glycolic acid)–polyethylene glycol–folic acid nanoparticles: a novel biodegradable nanocarrier for secure and efficient antitumor drug delivery

Chen¹,

Wu²,

Luo³

et al. 2017

IJN

View full text Add to dashboard Cite

Further specific target-ability development of biodegradable nanocarriers is extremely important to promote their security and efficiency in antitumor drug-delivery applications. In this study, a facilely prepared poly(lactic- co -glycolic acid) (PLGA)–polyethylene glycol (PEG)–folic acid (FA) copolymer was able to self-assemble into nanoparticles with favorable hydrodynamic diameters of around 100 nm and negative surface charge in aqueous solution, which was expected to enhance intracellular antitumor drug delivery by advanced dual tumor-target effects, ie, enhanced permeability and retention induced the passive target, and FA mediated the positive target. Fluorescence-activated cell-sorting and confocal laser-scanning microscopy results confirmed that doxorubicin (model drug) loaded into PLGA-PEG-FA nanoparticles was able to be delivered efficiently into tumor cells and accumulated at nuclei. In addition, all hemolysis, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, and zebrafish-development experiments demonstrated that PLGA-PEG-FA nanoparticles were biocompatible and secure for biomedical applications, even at high polymer concentration (0.1 mg/mL), both in vitro and in vivo. Therefore, PLGA-PEG-FA nanoparticles provide a feasible controlled-release platform for secure and efficient antitumor drug delivery.

show abstract

“…MP tienen un tamaño de 0,1 a 100 µm y las NP de 0,1 a 100 nm (1 nm = 1 x 10 -6 mm) (Riehemann et al, 2009;Kamaly et al, 2016). Esta diferencia en su escala de tamaño se torna altamente significativa al comparar la superficie de contacto que representa cada sistema.…”

Section: Micropartículas Poliméricasunclassified

Proteína Morfogenética Ósea y su Opción como Tratamiento de la Fisura Alveolar

et al. 2017

View full text Add to dashboard Cite

1,10URIBE, F.; CANTÍN, M.; ALISTER, J.P.; VILOS, C.; FARIÑA, R. & OLATE, S. Proteína morfogenética ósea y su opción como tratamiento de la fisura alveolar. Int. J. Morphol., 35(1):310-318, 2017.RESUMEN:La proteína morfogenética ósea (BMP), es una proteína endógena que ha mostrado efectos significativos en la promoción de la formación ósea. El uso de BMP ha sido descrito en la reconstrucción de defectos óseos de origen traumáticos y patológicos, incluyendo la fisura alveolar, el aumento de reborde alveolar, la elevación de seno maxilar, el injerto de alveolo post-extracción, y la cirugía perimplantaria entre otros. A pesar de las ventajas asociadas al uso de BMP y que en la actualidad se aplica en combinación con matrices de colágeno, ciertas propiedades tales como su baja resistencia mecánica y su elevada tasa de liberación inicial disminuyen su eficacia en la formación ósea. En este contexto, el desarrollo de nuevos sistemas de liberación prolongada de BMP que permitan la quimiotaxis de células mesenquimáticas y su posterior diferenciación a osteoblastos representa un desafío con alto potencial clínico para la estimulación de la formación ósea. En este trabajo, se describe el uso de BMP en la reconstrucción de fisuras alveolares y en particular se discuten las ventajas de su administración en micropartículas poliméricas como sistemas de liberación de BMP (rhBMP-2) con promisorias aplicaciones en la estimulación de la formación ósea.PALABRAS CLAVE: Proteína morfogenética ósea; rhBMP-2; Fisura alveolar; Micropartículas. INTRODUCCIÓNLas proteínas morfogenéticas óseas (BMPs) son un conjunto de proteínas endógenas que pertenecen a la familia de factor de crecimiento transformante beta (TGF-β) y que tienen la capacidad de inducir formación del hueso, cartílago y el tejido conectivo (Carreira et al., 2014a).Las BMPs fueron descritas por el Dr. Marshal Urist en 1965(Urist, 1965, al implantar matriz ósea desmineralizada extraída de bovino a nivel intramuscular en ratas y conejos y observar la producción ósea ectópica en el sitio de implantación; él lo denominó formación ósea por autoinducción. Urist atribuyó el proceso a la presencia de una proteína que atrae células mesenquimáticas pluripotenciales e induce formación ósea local, por lo que la denominó proteína morfogenética ósea (BMP). Actualmente, se han identificado 20 tipos distintos de BMP, sin embargo sólo la BMP-2, BMP-7 y BMP-9 son capaces de promover la osteoinducción. Pese a que BMP es una proteína endógena que puede ser obtenida de tejido óseo desmineralizado, su aislamiento es inviable debido a que se encuentra en mínimas cantidades (Wozney et al., 1988). Estudios descritos en bovinos mostraron que es posible obtener 57 mg de un extracto rico en BMPs por kilo de hueso fresco. Sin embargo, luego de realizar los procesos de purificación y aislamiento de una BMP en específi-co, el rendimiento se redujo a unos cuantos ng de BMP por kg de hueso (Carreira et al., 2014a).Por otra parte, basados en las posibles reacciones inmunológicas que pueden ocasionar la utili...

show abstract

Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release

Cited by 2,207 publications

References 594 publications

Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles

Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles

Dual tumor-targeted poly(lactic-<em>co</em>-glycolic acid)–polyethylene glycol–folic acid nanoparticles: a novel biodegradable nanocarrier for secure and efficient antitumor drug delivery

Proteína Morfogenética Ósea y su Opción como Tratamiento de la Fisura Alveolar

Contact Info

Product

Resources

About

Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release

Cited by 2,207 publications

References 594 publications

Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles

Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles

Dual tumor-targeted poly(lactic-<em>co</em>-glycolic acid)&ndash;polyethylene glycol&ndash;folic acid nanoparticles: a novel biodegradable nanocarrier for secure and efficient antitumor drug delivery

Proteína Morfogenética Ósea y su Opción como Tratamiento de la Fisura Alveolar

Contact Info

Product

Resources

About

Dual tumor-targeted poly(lactic-<em>co</em>-glycolic acid)–polyethylene glycol–folic acid nanoparticles: a novel biodegradable nanocarrier for secure and efficient antitumor drug delivery